Cover Image




Introduction - ANA negative systemic
lupus erythematosus (SLE) is a relatively
uncommonentity in childhood but when it
occurs is usually associated with significant
multi-system involvementespecially
renal. Aim - To describe the clinical profile,
treatment and outcome of children
with ANAnegative SLE.Methodology -
160 children with SLE were being followed
up in Pediatric Rheumatologyand
Pediatric Nephrology clinic. Out of this,
16 children were diagnosed to have ANA
negative SLEwas included in the study.
Their clinical, laboratory, treatment and
outcome data were collected fromtheir
medical records and entered in the proforma
and analyzed.Results - Total of 16
children werefollowed up with ANA negative
SLE. 13 (82) were girls and 3 (18)
were boys. Mean age at diagnosiswas
10.4 years (range 7 to 14 years). ACR
classification criteria for SLE were fulfilled
by 5 (31)children. 14 (88) had renal
involvement. All underwent renal biopsy.
Among these,
WHO Class IVlupus nephritis (81) was the
most common histopathological finding. All
the children had received steroids for the
treatment of ANA negative SLE. Cyclophosphamide
was used in 3 (19), mycophenolate
mofetil was used in 4 (25) and
hydroxychloroquine was used in 9 (56) children.
8 (50) of the children had attained
complete remission, 3 (19) had attained
partial remission and 5 (31) had not attained
remission at the end of the follow
up. None of the children had become ANA
positive during the follow up period. 7(44)
patients had flares during the follow up and
the maximum number of flares in a single
patient was 3 episodes.Conclusion - ANA
negative SLE is a rare entity in childhood.
We found a prevalence of 10 in our SLE
children. Renal involvement was predominant
manifestation in our series of children.
Treatment with steroids showed adequate
response in these children.
WHO Class IVlupus nephritis (81) was the
most common histopathological

Full Text:



COONS AH, KAPLAN MH. Localization

of antigen in tissue cells; improvements

in a method for the detection of

antigen by means of fluorescent antibody.

J. Exp. Med. 1950 Jan 1;91(1):1


Tan EM, Cohen AS, Fries JF, Masi

AT, McShane DJ, Rothfield NF, et al.

The 1982 revised criteria for the classification

of systemic lupus erythematosus.

Arthritis Rheum. 1982 Nov;25


Hochberg MC. Updating the American

College of Rheumatology revised

criteria for the classification of systemic

lupus erythematosus.

Arthritis Rheum. 1997 Sep;40 (9):1725.

Koller SR, Johnston CL Jr, Moncure

CW. Lupus erythematosus cell preparation-

antinuclear factor incongruity. A review

of diagnostic tests for systemic lupus

erythematosus. Am. J. Clin. Pathol.


Cross LS, Aslam A, Misbah SA. Antinuclear

antibody-negative lupus as a

distinct diagnostic entity--does it no

longer exist? QJM. 2004 May;97(5):303


McHardy KC, Horne CH, Rennie J.

Antinuclear antibody-negative systemic

lupus erythematosus-how common? J.

Clin. Pathol. 1982 Oct; 35(10):1118–

Wallace DJ, Linker-Israeli M. It’s not

the same old lupus or Sjögren’s any

more: one hundred new insights, approaches,

and options since 1990.

Curr Opin Rheumatol. 1999 Sep;11


Tozzoli R, Bizzaro N, Tonutti E,

Villalta D, Bassetti D, Manoni F, et al.

Guidelines for the laboratory use of

autoantibody tests in the diagnosis and

monitoring of autoimmune rheumatic

diseases. Am. J. Clin. Pathol. 2002


Kavanaugh A, Tomar R, Reveille J,

Solomon DH, Homburger HA. Guidelines

for clinical use of the antinuclear

antibody test and tests for specific

autoantibodies to nuclear antigens.

American College of Pathologists.

Arch. Pathol. Lab. Med. 2000 Jan;124


Gottlieb BS, Ilowite NT. Systemic

Lupus Erythematosus in Children and

Adolescents. Pediatrics in Review.


Gianviti A, Barsotti P, Barbera V,

Faraggiana T, Rizzoni G. Delayed onset

of systemic lupus erythematosus in

patients with “full-house” nephropathy.

Pediatr. Nephrol. 1999 Oct;13(8):683–


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.

An initiative of The Tamil Nadu Dr M.G.R. Medical University